Destiny Pharma plc announced the appointment of Dr. Yuri Martina as Chief Medical Officer (CMO). Yuri brings to the company more than 20 years' experience and an extensive record of excellence in clinical development and successful interactions at the highest levels with key regulatory, industry and government stakeholders including the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and the Japanese Pharmaceutical and Medical Device Agency (PMDA). Most recently, Yuri was Senior Vice President Development and deputy CMO at Grünenthal Group where he was a key member of the Global R&D Leadership and the Global Commercial Leadership Teams.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.25 GBX | +3.17% | -4.41% | -76.79% |
Apr. 25 | Norcros sells Johnson Tiles UK; Trifast trading well | AN |
Apr. 25 | Transcript : Destiny Pharma plc, 2023 Earnings Call, Apr 25, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.79% | 19.62M | |
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |
- Stock Market
- Equities
- DEST Stock
- News Destiny Pharma plc
- Destiny Pharma plc Appoints Yuri Martina as Chief Medical Officer